Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.47 |
| ▸ | DHODH | Q02127 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | C1R | P00736 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410865 | 1.00 | TAS2R14 (0.47) | TAS2R14DHODHALDH1A1HPGDKMO | |
| SCHEMBL31407282 | 0.87 | PARP1 (0.46) | TAS2R14ALDH1A1HPGDKMOCTNNB1 | |
| SCHEMBL29575721 | 0.85 | NR4A2 (0.47) | TAS2R14ALDH1A1HPGDKDM4E | |
| SCHEMBL2024463 | 0.85 | NR4A2 (0.47) | TAS2R14ALDH1A1HPGDKDM4E | |
| SCHEMBL16549389 | 0.83 | KDM4E (0.56) | ALDH1A1KDM4E | |
| SCHEMBL2359387 | 0.82 | EIF4E (0.41) | TAS2R14DHODHALDH1A1HPGDHDAC6 | |
| SCHEMBL23275797 | 0.81 | KDM4E (0.44) | ALDH1A1KDM4E | |
| SCHEMBL29410845 | 0.81 | KDM4E (0.44) | ALDH1A1KDM4E | |
| SCHEMBL2541630 | 0.81 | F7 (0.43) | ALDH1A1KDM4ENOTUM | |
| SCHEMBL30889359 | 0.80 | KDM4E (0.45) | ALDH1A1CTNNB1WNT3AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114456098-B | Preparation method of medicine Ai Shali ketone for treating diabetic nephropathy | 大连理工大学 | 2024-06-14 | — | — | CN | claimed |
| CN-114456098-A | Preparation method of diabetic nephropathy medicine namely elsamiloride | 大连理工大学 | 2022-05-10 | — | — | CN | claimed |
| US-12527763-B2 | Pyrrole amide compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2026-01-20 | — | — | US | disclosed |
| CN-114456098-B | Preparation method of medicine Ai Shali ketone for treating diabetic nephropathy | 大连理工大学 | 2024-06-14 | — | — | CN | disclosed |
| US-20220211665-A1 | PYRROLE AMIDE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| CN-114702427-A | Pyrrole amide compound and application thereof | 年衍药业(珠海)有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114456098-A | Preparation method of diabetic nephropathy medicine namely elsamiloride | 大连理工大学 | 2022-05-10 | — | — | CN | disclosed |
| CN-112707854-B | Pyrrole amide compound and application thereof | 年衍药业(珠海)有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-3950674-A1 | PYRROLE AMIDE COMPOUND AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021078135-A1 | PYRROLE AMIDE COMPOUND AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-29 | — | — | WO | disclosed |
| CN-112707854-A | Pyrrole amide compound and application thereof | 广东东阳光药业有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-105164105-A | Crystal of pyrrole derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2015-12-16 | — | — | CN | disclosed |
| US-8754118-B2 | Atropisomer of pyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20140024696-A1 | ATROPISOMER OF PYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8524918-B2 | Atropisomer of pyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20100093826-A1 | ATROPISOMER OF PYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2133330-A1 | ATROPISOMER OF PYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527763-B2 | Pyrrole amide compound and use thereof | NR3C2, AVPR2, MC2R | TAS2R14 539/4885DHODH 1374/4885ALDH1A1 2126/4885 |
| US-20140024696-A1 | ATROPISOMER OF PYRROLE DERIVATIVE | CYP11B2, CYP11B1, PYCR1 | TAS2R14 4282/4885DHODH 1684/4885ALDH1A1 840/4885 |
| US-20100093826-A1 | ATROPISOMER OF PYRROLE DERIVATIVE | CYP11B2, CYP11B1, PYCR1 | TAS2R14 4282/4885DHODH 1684/4885ALDH1A1 840/4885 |
| US-20220211665-A1 | PYRROLE AMIDE COMPOUND AND USE THEREOF | MC2R, NR3C2, AVPR2 | TAS2R14 1140/4885DHODH 1615/4885ALDH1A1 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.